Zacks Small Cap Research on MSN

ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in ...
ascopubs.org

Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results Twenty-eight ...
Cure Today

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

Exceptional responses in RCC are associated with higher clonal neoantigen load and enriched B-cell receptor signaling pathways. Tertiary lymphoid structure signatures and increased metabolic activity ...
eLife

Receptor Proteins: Lipids challenge ligands to control receptors

The behaviour of a receptor protein can be influenced by the presence of certain lipids in the membrane it is embedded in.